Abstract
Dual antiplatelet therapy (aspirin plus clopidogrel) is mandatory in patients treated with coronary stent implantation. This strategy is highly effective in prevention of stent thrombosis until its struts are covered with endothelium. However, a substantial number of patients still suffer from recurrent ischemic coronary events despite adequate antiplatelet therapy. These events fall into three categories: stent thrombosis, in stent restenosis and events related to other nonstented coronary lesions. Some data suggest that beside other local and systemic factors resistance to aspirin and clopidogrel may be a possible cause of stent thrombosis and ischemic events in patients after coronary interventions. Several mechanisms of antiplatelet drug resistance have been reported including poor compliance, interactions with other drugs, genetic polymorphism or increased platelet turnover. More research is needed to adequately assess the clinical significance and prognostic value of antiplatelet drug resistance detected by laboratory tests in patients undergoing percutaneous intervention. We review published data on mechanisms and the clinical significance of aspirin and clopidogrel resistance in patients after coronary interventions.
Keywords: Aspirin and clopidogrel resistance, percutaneous coronary interventions
Current Vascular Pharmacology
Title: Significance of Aspirin and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Interventions
Volume: 5 Issue: 2
Author(s): Jerzy Pregowski, Adam Witkowski and Dariusz Sitkiewicz
Affiliation:
Keywords: Aspirin and clopidogrel resistance, percutaneous coronary interventions
Abstract: Dual antiplatelet therapy (aspirin plus clopidogrel) is mandatory in patients treated with coronary stent implantation. This strategy is highly effective in prevention of stent thrombosis until its struts are covered with endothelium. However, a substantial number of patients still suffer from recurrent ischemic coronary events despite adequate antiplatelet therapy. These events fall into three categories: stent thrombosis, in stent restenosis and events related to other nonstented coronary lesions. Some data suggest that beside other local and systemic factors resistance to aspirin and clopidogrel may be a possible cause of stent thrombosis and ischemic events in patients after coronary interventions. Several mechanisms of antiplatelet drug resistance have been reported including poor compliance, interactions with other drugs, genetic polymorphism or increased platelet turnover. More research is needed to adequately assess the clinical significance and prognostic value of antiplatelet drug resistance detected by laboratory tests in patients undergoing percutaneous intervention. We review published data on mechanisms and the clinical significance of aspirin and clopidogrel resistance in patients after coronary interventions.
Export Options
About this article
Cite this article as:
Pregowski Jerzy, Witkowski Adam and Sitkiewicz Dariusz, Significance of Aspirin and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Interventions, Current Vascular Pharmacology 2007; 5 (2) . https://dx.doi.org/10.2174/157016107780368262
DOI https://dx.doi.org/10.2174/157016107780368262 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Infrequent Infections in COPD
Current Respiratory Medicine Reviews Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?
Current Vascular Pharmacology Epidural Steroid Injections Do Not Induce Weight Gain
Current Drug Safety Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Cognition in Non-Demented Diabetic Older Adults
Current Aging Science Coronary Microvascular and Cardiac Dysfunction Due to Homocysteine Pathometabolism; A Complex Therapeutic Design
Current Pharmaceutical Design Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?
Current Pharmaceutical Design Current View from Alzheimer Disease to Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Melanocortin - 4 Receptor Agonists for the Treatment of Obesity
Current Topics in Medicinal Chemistry Specific Nutritional Needs for Children. Are Children Small Adults?
Current Nutrition & Food Science The Malignant Obesity Hypoventilation Syndrome (MOHS)
Current Respiratory Medicine Reviews Molecular Basis of Obesity: Current Status and Future Prospects
Current Genomics Pediatrics for Disability: A Comprehensive Approach to Children with Syndromic Psychomotor Delay
Current Pediatric Reviews Focus on the Correlations between Alzheimer’s Disease and Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease
Current Vascular Pharmacology Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Metabolic Syndrome in HIV-patients in Antiretroviral Therapy
Current HIV Research Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all
Current Pharmaceutical Design Synthesis and SAR Studies of Urea and Thiourea Derivatives of Gly/Pro Conjugated to Piperazine Analogue as Potential AGE Inhibitors
Protein & Peptide Letters